Novel cell-based immunization technology and functional validation of resulting antibodies
Beschreibung
Development of a novel immunization method in rabbits that improves the generation of antibodies against the native form of human proteins e.g. cell surface receptors. Subsequent validation of the method through functional characterization of candidate therapeutic antibodies in vitro and in vivo. The aim is the discovery of monoclonal antibodies as novel therapeutics for two different first in class targets in cancer.
Eckdaten
Projektleitung
Stellv. Projektleitung
Dr. Bruno Filippi
Co-Projektleitung
Dr. Philippe Krebs, Prof. Dr. Frank Stenner
Projektteam
Bettina Keller Abu Seda, Jenny Pally, Leopold von Balthazar
Projektpartner
Memo Therapeutics AG
Projektstatus
abgeschlossen, 12/2017 - 11/2020
Institut/Zentrum
Institut für Chemie und Biotechnologie (ICBT)
Drittmittelgeber
KTI-Projekt / Projekt Nr. 26019.2 PFLS-LS
Projektvolumen
1'581'835 CHF